Opinion|Videos|August 1, 2024
Managing Bronchiectasis: Treatment Goals, Outcome Measures, and Clinical Decision Resources
Author(s)Panagis Galiatsatos, MD
Panagis Galiatsatos, MD, MHS, provides clinical insights on resources and factors that inform the treatment of patients with bronchiectasis.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How do treatment goals and outcome measures for bronchiectasis differ from those of COPD, particularly regarding FEV and exacerbation rates?
- In the absence of U.S.-based treatment guidelines, what resources do you use to make clinical decisions for bronchiectasis management?
Advertisement
Related to this article
Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5